3.22
+0.14(+4.55%)
Currency In USD
| Previous Close | 3.08 |
| Open | 3.1 |
| Day High | 3.33 |
| Day Low | 2.91 |
| 52-Week High | 4.34 |
| 52-Week Low | 1.41 |
| Volume | 791,205 |
| Average Volume | 1.41M |
| Market Cap | 116.23M |
| PE | -5.28 |
| EPS | -0.61 |
| Moving Average 50 Days | 2.74 |
| Moving Average 200 Days | 2.05 |
| Change | 0.14 |
If you invested $1000 in Gain Therapeutics, Inc. (GANX) since IPO date, it would be worth $263.93 as of December 25, 2025 at a share price of $3.22. Whereas If you bought $1000 worth of Gain Therapeutics, Inc. (GANX) shares 3 years ago, it would be worth $1,075.13 as of December 25, 2025 at a share price of $3.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever observation following the administration of a GCase
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
GlobeNewswire Inc.
Nov 20, 2025 12:00 PM GMT
GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in α-synuclein-induced mouse PD model GT-02287 improves mit
Gain Therapeutics to Present at Neuroscience 2025
GlobeNewswire Inc.
Oct 30, 2025 11:00 AM GMT
BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the